22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
20:13 , Feb 10, 2017 |  BC Week In Review  |  Company News

Telix, Atlab deal

Telix and single-asset company Atlab partnered to develop radiolabeled variants of Atlab's huJ591 to treat metastatic prostate cancer. Telix also gained an exclusive option to acquire Atlab and has one year to exercise the option....
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ATL101: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 41 evaluable previously treated patients with metastatic CRPC showed that the recommended Phase II dose of ATL101 - 2 doses of 40-45 mCi/m 2 ATL101 given 2...